Name: Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis (en Inglés)
Price: 607.85 PEN
Availability: InStock
Author: Hommes, O. R. ; Comi, G.
ISBN: 9788847021716

portada Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis (en Inglés)

Formato

Libro Físico

Autor

G. Comi

O. R. Hommes

Editorial

Springer

Idioma

Inglés

N° páginas

199

Encuadernación

Tapa Blanda

Dimensiones

23.4 x 15.6 x 1.2 cm

Peso

0.31 kg.

ISBN13

9788847021716

Categorías

Radioterapia
Neurología y neurofisiología clínicas
Medicina nuclear
Técnicas de diagnóstico por la imagen: radiología

Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis (en Inglés)

G. Comi (Autor) · O. R. Hommes (Autor) · Springer · Tapa Blanda

Libro Nuevo

S/ 607,85

S/ 1.013,08

Ahorras: S/ 405,23

40% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Viernes 19 de Julio y el Martes 30 de Julio.

Lo recibirás en cualquier lugar de Perú entre 2 y 5 días hábiles luego del envío.

Reseña del libro "Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis (en Inglés)"

There is now evidence that irreversible brain damage accumulates very early in the course of multiple sclerosis. This book reviews the main neurobiological, magnetic resonance imaging, and clinical aspects of the early phases of the dis- ease. Mechanisms ofirreversible axonal damage and the role played by the inter- action of glia and the axon are highlighted. In contrast to what was believed for a long time, the sufficient availability of oligodendrocyte precursor cells to promote remyelination in acute lesions has now been demonstrated. For reasons not understood, this remyelination process fails or does not start, particularly in the chronic stages ofthe disease. These findings emphasize the importance of the "milieu" changes induced by an inflammatory process in limiting remyelination. However, first indications are that part of this inflammatory process may have a neuroprotective effect. Pathological studies in multiple sclerosis have now clearly demonstrated that destructive processes may be followed by recovery phases in such a way that myelin may be morphologically and functionally reconstituted. These findings provide the rationale for early treatment and emphasize the importance of clinical trials in early multiple sclerosis. Early treatment is one of the most important aspects in multiple sclerosis today.